| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.1M | — | -60.2% |
| SG&A Expense | $3.7M | — | -46.4% |
| Operating Income | -$12.8M | — | +57.0% |
| Net Income | -$12.4M | — | +57.6% |
| EPS (Basic) | -$0.17 | — | +78.8% |
| EPS (Diluted) | -$0.17 | — | +78.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $44.7M | -19.9% | +24.6% |
| Current Assets | $46.3M | -20.2% | +3.7% |
| Total Assets | $46.4M | -20.8% | -15.7% |
| Current Liabilities | $9.3M | -16.3% | -53.1% |
| Total Liabilities | $27.7M | -4.7% | +5.1% |
| Stockholders' Equity | $18.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.7M | — | +54.5% |
| Investing Cash Flow | $550K | — | — |
| Financing Cash Flow | $3.3M | — | +0.0% |
| -34.9% |